You are here

  • Home
  • Archive
  • Volume 21, Issue 2
  • Complete revascularisation in patients with ST-segment elevation myocardial infarction and multivessel disease: contemporary data in context

Article Text

Article menu
Download PDFPDF
Therapeutics/Prevention
Randomised controlled trial
Complete revascularisation in patients with ST-segment elevation myocardial infarction and multivessel disease: contemporary data in context
  1. Amerjeet S Banning1,
  2. Anthony H Gershlick2
  1. 1 Department of Cardiovascular Sciences, University of Leicester, Glenfield Hospital, University Hospitals of Leicester NHS Trust, Leicester, UK;
  2. 2 University of Leicester, Leicester, UK
  1. Correspondence to : Dr Amerjeet S Banning, Department of Cardiovascular Sciences, University of Leicester, Glenfield Hospital, University Hospitals of Leicester NHS Trust, Groby Road, Leicester, LE3 9QP, UK; ab758{at}le.ac.uk

https://doi.org/10.1136/ebmed-2015-110315

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Commentary on: Engstrøm T, Kelbæk H, Helqvist S, et al. DANAMI-3—PRIMULTI Investigators. Complete revascularisation versus treatment of the culprit lesion only in patients with ST-segment elevation myocardial infarction and multivessel disease (DANAMI-3—PRIMULTI): an open-label, randomised controlled trial. Lancet 2015;386:665–71.OpenUrlCrossRefPubMed

    Context

    Primary percutaneous coronary intervention is recommended in patients presenting with ST-segment Elevation Myocardial infarction (STEMI).1 In 40–60% of STEMI patients there is disease in non-infarct-related arteries (IRAs).2 Such patients have higher mortality rates and incidence of MI.3 Current guidelines suggest PCI should be undertaken to the IRA only.1 However, these were based on numerous, potentially selected-patient retrospective observational studies. The DANAMI-3-PRIMULTI investigators compared complete and culprit-only revascularisation in patients with STEMI and multivessel disease.

    Methods

    PRIMULTI was a prospective multicentre open-label randomised controlled trial. Patients within 12 h of STEMI were initially …

    View Full Text

    Footnotes

    • Contributors Both authors contributed to the submitted commentary. ASB and AHG reviewed the original article and wrote the manuscript.

    • Competing interests None declared.

    • Provenance and peer review Commissioned; internally peer reviewed.